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Abstract Botulinum toxin type A
(BoNT-A) has been recently sug-
gested as prophylaxis therapy for
the treatment of primary headache
chronic forms. Several studies on
its efficacy are available, but
results are often contradictory and
not univocal. The effects of BoNT-
A on chronic forms of both ten-
sion-type headache and migraine
have been investigated. In this
study we introduce our five-year
long experience with BoNT-A
(BOTOX, Allergan, Irvine, CA).
The employed dosage was 100 U
and the Fixed Sites–Fixed Doses
(FSFD) protocol was used. The
period of study was April 2001 to
July 2006. A sum of 1347 patients
suffering from chronic daily
headache (CDH) were treated. We
registered in these patients the
number of headache days per
month and observed their reduction
in relation to the number of injec-
tions. The best results were found
after 12 months of treatment, with
patients being free of attacks 23
days per month. The BoNT-A treat-
ment was safe and well tolerated,
as only 1.6% of patients reported
adverse events, and they were all
mild and transient. In conclusion,
BoNT-A therapy appears to be an
efficacious new therapeutic choice
in the prophylaxis of CDH, espe-
cially for patients not responding to
previous prophylactic treatments.
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Headache is among the most common symptoms requiring a
physician consultation, and therefore one of the major issues
in public health [1]. Approximately 51% of the general pop-
ulation is affected by headache, of which 33% are affected
by tension-type headache (TTH), 14% by migraine and 4%
by chronic forms (chronic daily headache, CDH). In CDH,
attacks occur at least 15 days per month, for three months
consecutively. Incidence is higher in women than in men [2].
Reduced work ability and absence from work are
reported by a range of 7%–15% of this population.
Considering only migraine, the number of lost working
days per year varies between 2 and 6 [3].
Patients experiencing medium/high monthly attacks
need preventative therapy. Botulinum toxin type A (BoNT-
A) has been recently proposed as a new option in this
approach. At present, this drug plays a possible role in the
treatment of both chronic forms of TTH and migraine [4, 5].
In clinical practice, BoNT-A (BOTOX, Allergan,
Irvine, CA) is currently applied to various conditions
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including post-stroke disability, cervical dystonia, ble-
pharospasm, regional myofascial pain syndromes like
hemifacial spasm, and other disorders involving patholog-
ic muscle hyperactivity [6].
Against this background, BoNT-A may be considered
as a possible therapeutic choice in TTH management, as
suggested by increased muscular tension and tenderness
in several TTH patients, together with other factors, both
peripheral and central, such as stress and psychopatholog-
ical factors [7].
Mechanisms of action
BoNT-A is a substance synthesised from the gram-positive
anaerobic bacterium Clostridium botulinum. It acts by
blocking the peripheral release of acetylcholine at the level
of peripheral cholinergic nerve endings [8]. In fact, BoNT-
A reaches the extra-cellular space through transport in the
general vascular circulation. Unfortunately, the mechanism
conducing BoNT-A outside the vasculature is unknown.
The neuromuscular junction, which constitutes its princi-
pal target, is reached in the extra-cellular space. Botulinum
toxin also arrests exocytosis in all the peripheral choliner-
gic sites [9]. At the neuromuscular junction level, BoNT-A
blocks spontaneous quantal release of acetylcholine via
cleavage of SNAP-25 protein (synaptosomal protein with a
molecular weight of 25 kDa), producing muscular relax-
ation. This mechanism of action is responsible for both the
botulism disorder and the use of BoNT-A as a therapeutic
agent in clinical practice. Among the seven known
serotypes (going from A to E), BoNT-A represents the most
investigated in clinical studies. Besides, BoNT-A displays
the most sustained action [10]. Major effects can be
observed 5 or 6 weeks after the intramuscular injection.
Recovery usually occurs 12 weeks after the injection, the
required period for the regeneration of the nerve endings
[9]. For that reason, in therapeutic programmes injection
cycles are repeated every three months. Furthermore,
BoNT-A action on pain modulation processes could play a
predominant role in the prophylactic treatment of TTH.
BoNT-A inhibits the release of calcitonin gene-related pep-
tide (CGRP), as demonstrated by Durham et al. In this
study, CGRP was expressed in trigeminal ganglia neurons
present in 1–3-day-old cultures, incubated afterwards with
toxin. This incubation shows the reduction of the secretory
stimulation of CGRP neurotransmitter with respect to con-
trol cultures [11]. These data suggest a contribution of
CGRP to migraine pathophysiology. CGRP causes, togeth-
er with other peptides, the release of proinflammatory
mediators that increase CGRP synthesis, in correspon-
dence with the duration of a typical migraine episode [12].
Consequently, BoNT-A could be extended also to the treat-
ment of this disorder [13]. Eross et al. demonstrated the
efficacy of reducing headache frequency in patients affect-
ed by episodic and chronic migraine [14]. Besides, sup-
pressive effects of BoNT-A on intradermal capsaicin-
evoked pain and secondary hyperalgesia have been demon-
strated, suggesting a local peripheral effect on cutaneous
nociceptors [15].
BoNT-A in headache treatment
In the literature, discordant opinions exist concerning
BoNT-A therapy in primary headache disorders according
to ICDH-II criteria [16]. However, BoNT-A seems partic-
ularly useful for CDH. In fact, the treatment of CDH is
often still inadequate [17]. There is a need for new effec-
tive, safe and manageable prophylactic drugs, rather than
the umpteenth triptan [18, 19].
But the debate has seen Blumenfeld defining BoNT-
A as a “rational treatment choice” [20] and Welch
affirming BoNT-A’s beneficial effects, which remain
unproven [21].
The analysis of recent clinical trials with BoNT-A in
headache prophylaxis reported diverse information.
These studies are often structured quite differently con-
cerning population selection, choice of outcome and
study duration. Some studies in favour of BoNT-A are the
following. In an 11-month, randomised, double-blind,
placebo-controlled study, Dodick et al. enrolled 355
patients affected by CDH, of which 228 were not under
prophylaxis treatment. Those patients received three
treatment cycles (BoNT-A or placebo) every 90 days.
After the first month, BoNT-A consistently reduced
headache frequency, and its effect persisted for 2 or 3
months. Headache frequency diminished in over 50% of
patients after two BoNT-A injection sessions, and the
mean number of headache-free days per month was
almost tripled (from 6 to 16 days). Furthermore, drug
consumption decreased remarkably [22].
Similar results were shown by Mathew et al. [23].
Patients treated with BoNT-A presented 7 more (1 week)
headache-free days with respect to their baseline. The ini-
tial difference between the groups consisting in 1.5
headache-free days did not prove to be statistically signif-
icant after 180 days.
At the same time, Relja and Telarovic´ included 16
patients with chronic TTH in a prospective double-
blind, placebo-controlled, cross-over study and 30
patients in an open-label long-term study, to investigate
the role of BoNT-A in prophylaxis. All patients experi-
enced a decrease in headache intensity and pericranial
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muscle tenderness, and an increase of headache-free
days, statistically significant compared to the placebo
group [24].
In a retrospective chart review, Blumenfeld observed a
reduction of 56% in the number of headache days per
month from 18.9 to 8.3 (n=256, p<0.001). Two hundred
and seventy-one patients were treated with BoNT-A from
January 1999 to February 2002 [25].
In contrast, Rollnik et al. [26] registered no significant
differences between placebo and BoNT-A after 4, 8, 12
weeks. In this double-blind, placebo-controlled study,
with 21 patients affected by TTH, no reduction was
observed in terms of attack frequency, analgesics intake,
total tenderness score evaluated through palpation and
quality of life parameters. However, the great limitation of
this pilot study was the unique drug dosage (20 U).
Silberstein et al. evaluated the efficacy of various
dosages (50, 100 and 150 U injected in 5 muscle groups
and 86 and 100 U injected in three muscle groups). In
this study as well, both control and BoNT-A groups
were found to be equivalent. For tension headache-free
days per month, all groups improved at the day 60 pri-
mary endpoint, while after 90 days a 50% decrease in
terms of headache days was observed in BoNT-A
patients. This suggests the necessity of a longer evalua-
tion period [27].
Evers and Olesen recently predicted “the end of the
road” for BoNT-A. After having reviewed the published
data they conclude there is no possible role for this treat-
ment [28]. We do not share this opinion [17].
A long list of studies, which cannot be discussed here,
represent “pro” and “cons” factions [29–40].
Five-year experience with BoNT-A in CDH
In our five-year-long experience at the Regional Referral
Headache Centre of the Sant’Andrea Hospital, BoNT-A
has been employed in prophylaxis therapy of CDH. The
Fixed Sites-Fixed Doses (FSFD) protocol used considered
the following pericranial muscles: frontalis, anterior tem-
poralis, occipitalis, trapezius, semispinalis capitis and/or
splenius capitis.
A total dosage of 100 U was administered every three
months during the first year of treatment, and afterwards
twice a year.
From 2001 to 2006, 1347 patients were treated in our
centre in a Day Hospital regimen, with an average of 350
patients per year over the last three years (Fig. 1).
We registered in these patients a frequency reduction
of headache days per month, increasing in time. The
maximum reduction was reached after 12 months of
treatment, with patients being free of attacks 23 days per
month (Fig. 2).
The first three-month cycle accomplished a maximum of
10 headache-free days per month. The improved results after
that suggest a major efficacy of a longer treatment (Fig. 2).
Fig. 1 Number of CDH patients under prophylaxis treatment with
BoNT-A
Fig. 2 Headache frequency in CDH patients after BoNT-A admin-
istration
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In 2001 about 25% of the patients had been undergo-
ing concomitant prophylaxis therapies (myorelaxants,
antidepressants, etc.), while in the following years only
5% of the patients were co-treated with an additional pro-
phylaxis therapy (Fig. 3). In the first two years, the num-
ber of total drop-outs represented 20%, which was
reduced to 12% in 2006 (Fig. 4).
As recorded in the literature the percentage of adverse
events is extremely low, BoNT-A appearing to be there-
fore safe and well tolerated [20–23]. In our data, only
1.6% of patients reported side effects. Forty-two percent
of these patients reported pain at the injection site, 41%
cutaneous irritation, 6% neck muscle rigidity, 6% nausea,
4% dizziness and 1% ptosis/dysphonia/dysphagia (Fig. 5).
All these side effects were mild and transient.
Health economics considerations on BoNT-A use in
headache lead us towards interesting views on its savings.
One year of in-hospital BoNT-A therapy amounts to
€564.00 including pharmaceutical costs, consumable sup-
plies and personnel. The total cost of BoNT-A treatment
per patient was €642.00, whilst average costs of previous
therapies amounted to €853.43 [41, 42]. This can be con-
sidered together with a reduction of clinic symptomatol-
ogy and analgesic intake [43].
Conclusions
On the basis of our clinical experience of BoNT-A off-
label application in CDH, the preferred subgroup for
BoNT-A application seems to be the non-responder CDH
patients. As the majority of these patients come from
detoxification procedures, we thought this application
could constitute a new option. There is clearly a higher
compliance for a prophylaxis therapy using a different
method of administration if compared to the traditional
treatment per os. CDH patients with medication overuse
headache (MOH) usually lose perception of the difference
between acute or preventative drugs, as they consume an
undetermined number of tablets daily. Therefore, the
injection approach with BoNT-A was apparently more
accepted after detoxification. The role of placebo in this
unusual administration pathway should be attentively
evaluated. Further studies dealing with this clinical topic
in double-blind phase III are in fieri and soon we will be
able to define BoNT-A’s efficacy in CDH patients non-
responders to previous therapies.
However, labeled preventative therapy for chronic
headaches remains inadequate. The drugs used are old and
often produce side effects. The poor efficacy of the avail-
able drugs and their unacceptable side effects often create
the pathway for abuse of pain-relief drugs and then MOH.
In conclusion, BoNT-A therapy appears to be an effi-
cacious new therapeutic choice in the prophylaxis of
CDH, especially for patients not responding to previous
prophylactic treatments. New upcoming data will defini-
tively clarify this issue.
Fig. 3 CDH patients co-treated with additional prophylaxis therapies
Fig. 4 Total drop-outs in CDH therapy with BoNT-A
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